Febrile neutropenia
DOI:
https://doi.org/10.1016/hscr.v40i1.273117Keywords:
Febrile neutropenia, mortality rateAbstract
Cancer is the leading cause of death in Thailand. Based on data from the National Cancer Institute, the number of new cancer diagnoses in 2022, 2023, and 2024 was 107,958, 129,024, and 99,732 respectively. In 2022, there were 118,829 deaths from cancer in Thailand. The leading cancer types of causing death are liver cancer, lung cancer, and colorectal cancer. Currently, there are many modality of treatment including surgery, radiotherapy and medical therapies like chemotherapy, targeted therapy and immunotherapy. A common severe complication from cancer treatment is febrile neutropenia which often required emergency hospital visits. The mortality rate of febrile neutropenia is approximately 10 percent. Therefore, prompt diagnosis and appropriate management of complications are crucial to lowering the mortality rate.
References
de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl 5):v252-v256. doi:10.1093/annonc/mdq226
Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(Suppl 5):v111-v118. doi:10.1093/annonc/mdw325
Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51-S59. doi:10.1016/j.ijantimicag.2007.07.014
Griffiths EA, Roy V, et al. Hematopoietic Growth Factors version 3.2024. NCCN Guidelines. 2024.
Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancerpatients. J Clin Oncol. 2000;18(15):3038-3051. doi:10.1200/JCO.2000.18.15.3038
Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33(15 suppl):465. doi:10.1200/jco.2015.33.15_suppl.465
Paesmans M, Klastersky J, Maertens J, et al. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer. 2011;19(7):1001-1008. doi:10.1007/s00520-010-0906-z
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93. doi:10.1093/cid/ciq042
Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med.1993;328(18):1323-1332. doi:10.1056/NEJM199305063281807
Raad I, Chaftari AM. Advances in prevention and management of central line-associated bloodstream infections in patients with cancer. Clin Infect Dis. 2014;59(Suppl 5):S340-S347. doi:10.1093/cid/ciu514
Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51-S59. doi:10.1016/j.ijantimicag.2007.07.014
Cho SY, Choi HY. Opportunistic fungal infection among cancer patients. A ten-year autopsy study. Am J Clin Pathol. 1979;72(4):617-621. doi:10.1093/ajcp/72.4.617
Link H, Böhme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 2003;82(Suppl 2):S105-S117. doi:10.1007/s00277-003-0713-3
Bell MS, Scullen P, McParlan D, et al. Neutropenic sepsis guidelines. Belfast: Northern Ireland Cancer Network; 2010. p.1-11.
Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(6):794-810. doi:10.1200/JCO.2012.45.2422
Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296-327. doi:10.1097/01.CCM.0000298158.07008.E3
Chemotherapy services in England: Ensuring quality and safety. London: National Chemotherapy Advisory Group; 2009.
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596. doi:10.1097/01.CCM.0000217961.16911.D3
Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality inpatients with febrile neutropenia. Antimicrob Agents Chemother. 2014;58(7):3799-3804. doi:10.1128/AAC.02685-13
Cohen MA, Lewis GM. Neurotropenic fever. J Emerg Med. 2006;31(2):227-233. doi:10.1016/j.jemermed.2005.08.016
André S, Taboulet P, Elie C, et al. Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Crit Care. 2010;14(2):R68. doi:10.1186/cc8954
Taccone FS, Artigas AA, Sprung CL, et al. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009;13(4):R15. doi:10.1186/cc7698
Clarke RT, Warnick J, Stretton K, Littlewood TJ. Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit. Br J Haematol. 2011;153(6):773-779. doi:10.1111/j.1365-2141.2011.08647.x
Keng MK, Thallner EA, Elson P, et al. Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department. J Oncol Pract. 2015;11(5):450-454. doi:10.1200/JOP.2014.002047
Lim C, Bawden J, Wing A, et al. Febrile neutropenia in EDs: the role of an electronic clinical practice guideline. Am J Emerg Med. 2012;30(1):5-10. doi:10.1016/j.ajem.2010.09.006
Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, and neutropenia. Clin Infect Dis. 2005;40(Suppl 4):S253-S259. doi:10.1086/427387
Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018;36(14):1443-1453. doi:10.1200/JCO.2017.77.1951
Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV. J Clin Oncol. 2013;31(10):1149-1157. doi:10.1200/JCO.2012.43.0808
Cornely OA, Wicke T, Seifert H, et al. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. Int J Hematol. 2004;79(1):74-79. doi:10.1007/BF02983759
Kibbler CC. Empirical antifungal therapy in febrile neutropenic patients: current status. Curr Top Med Mycol. 1997;8:5-19.
Feld R, DePauw B, Berman S, Keating A, Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol. 2000;18(21):3690-3698. doi:10.1200/JCO.2000.18.21.3690
Raad II, Escalante C, Hachem RY, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer. 2003;98(5):1039-1047. doi:10.1002/cncr.11586
Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systemic review and meta-analysis. Lancet Infect Dis. 2007;7(5):338-348. doi:10.1016/S1473-3099(07)70072-5
Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013;(6):CD003038. doi:10.1002/14651858.CD003038.pub3
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2011;52(4):e56-e93. doi:10.1093/cid/ciq042
Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25(2):247-259. doi:10.1086/514539
Wingard JR, Leather HL. Empirical antifungal therapy for the neutropenic patient. Oncology (Williston Park). 2001;15(3):351-360.
Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(31):3199-3212. doi:10.1200/JCO.2015.62.4570
Hamalainen S, Kuittinen T, Matinlauri I, et al. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences. Leuk Lymphoma. 2008;49(3):495-501. doi:10.1080/10428190701826075
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Health Science Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
